Terra Biological to Present Clinical Findings in ME/CFS and Long COVID at the International Association for Chronic Fatigue Syndrome (IACFS/ME)

Terra Biological to Present Clinical Findings in ME/CFS and Long COVID at the International Association for Chronic Fatigue Syndrome (IACFS/ME)

This year the Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis conference is virtual, Starting Wednesday July 27 through Saturday July 30.  Meeting events include workshops, a Keynote lecture by Akiko Iwasaki, PhD (Yale University) and Plenary Lectures by David Systrom, MD (Harvard Medical School), oral presentations and poster presentations.  Anyone with an interest in myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS), fibromyalgia, Long COVID, and dysautonomia is welcomed to attend.  Conference attendees with also receive online access to a recording of the oral presentations upon request.

For more information on the conference https://iacfsme.growthzoneapp.com/ap/Events/Register/nLvD5xgp?mode=Attendee

Dr. David Kaufman of the Center for Complex Disease will present Terra Biological’s findings in using oxaloacetate to treat ME/CFS and Long COVID fatigue.  In the six-week clinical trial there was:

  • Reduction of fatigue in Long COVID patients by up to 46.8%
  • Reduction of fatigue in ME/CFS patients by an average of 22.5% to 33%

The controlled clinical trial, using a dose escalating methodology, utilized ME/CFS patients who had been diagnosed for an average of 8.9 years and Long COVID patients with symptoms for at least 6 months. 

ME/CFS patients were given oxaloacetate doses of either 500 milligrams twice per day, 1,000 milligrams twice per day or 1,000 milligrams three times per day. Reduction in fatigue was dose dependent, with the smallest dose yielding a 21.7% reduction in fatigue and the largest yielding a 33.3% reduction in six weeks. Long COVID patients were given either 500 milligrams twice per day or 1000 milligrams of oxaloacetate twice per day, with fatigue reduced by up to 46.8% in six weeks.

The clinical trial results have been published in the Nature/Springer publication “Journal of Translational Medicine” https://pubmed.ncbi.nlm.nih.gov/35764955/ . 

Oxaloacetate, a human energy metabolite, is present in nearly every cell of the human body. Metabolomic studies in ME/CFS patients vs. normal controls indicate that oxaloacetate levels are significantly reduced in the plasma of ME/CFS patients. https://pubmed.ncbi.nlm.nih.gov/28059425/

Terra Biological will also discuss two ongoing confirmation clinical trials in ME/CFS.

High dosage Oxaloacetate is available as a medical food to treat your patients with the product “Oxaloacetate CFS”.  Each bottle of Oxaloacetate CFS contains ninety 500 mg capsules of oxaloacetate.

As a medical professional, we can set you up with a wholesale account to supply your patients with Oxaloacetate CFS.  We can also drop-ship the bottles directly to your patients.  Applications for wholesale accounts are at https://benagene.com/wholesale-signup

Should you have any questions regarding this study, or Oxaloacetate CFS, please do not hesitate to contact us.

Back to blog